| ||||||||||
|
Return to IndexStep 1: Taking Control of Your AsthmaStep 2: What is Asthma?Step 3: Know the SignsStep 4: How Asthma Is DiagnosedStep 5: The Levels of SeverityStep 6: Determine Your Goals and ExpectationsStep 7: Asthma DrugsStep 8: Drug Delivery DevicesStep 9: Understand Your Action PlanStep 10: Make "Peak Flow" a Habit!Step 11: Avoid Asthma TriggersStep 12: Visit Your Doctor RegularlyKey PointsGlossary *Close Menu* Return to IndexStep 1: Taking Control of Your AsthmaStep 2: What is Asthma?Step 3: Know the SignsStep 4: How Asthma Is DiagnosedStep 5: The Levels of SeverityStep 6: Determine Your Goals and ExpectationsStep 7: Asthma DrugsStep 8: Drug Delivery DevicesStep 9: Understand Your Action PlanStep 10: Make "Peak Flow" a Habit!Step 11: Avoid Asthma TriggersStep 12: Visit Your Doctor RegularlyKey PointsGlossary *Close Menu*
A new class of medications called Immunoglobulin E (IgE) inhibitors is available to treat allergy-related asthma. Omalizumab (Xolair) was the first approved therapy to target the IgE molecule. It is normal for your airways to tighten and become inflamed if you inhale a dangerous substance. This reaction is an attempt by your body to prevent the threat from traveling too far into your lungs. The airways open up again when the threat has passed. If you have allergy-induced asthma, however, your airways are overly responsive to mild substances called allergens. Your body's response to these triggers leads to blocked airways and the symptoms of asthma. Most asthma drugs relieve symptoms by simply "blunting" the response to an asthma trigger. In contrast, IgE blockers actually prevent the response from occurring in the first place. To understand this more fully, it helps to know what makes something an asthma trigger. If you have an allergy to a substance like pollen, mold, or dust mites (all called allergens), your body makes too many IgE antibodies to that substance. These antibodies recognize and fight against the individual allergens. But, having too many of the IgE antibodies can make the body too responsive to these allergens, and lead to an allergic reaction like asthma. Xolair binds to excess IgE antibodies in your bloodstream. This stops the IgE antibodies from recognizing the asthma-provoking allergens. In other words, omalizumab stops the body from overreacting to asthma triggers by making the IgE antibodies ineffective. This interrupts the excessive inflammatory response even before it starts. Xolair is given by injection every two to four weeks to prevent asthma flare-ups. Xolair was approved by the FDA in 2003 for patients ages 12 and older with moderate-to-severe persistent asthma. The most common side effect is an injection-site rash. IgE inhibitors also holds promise for the treatment of other forms of allergic disease.
Review Date:
May 25, 2005 Reviewed By: Alan Greene, M.D., F.A.A.P., Department of Pediatrics, Packard Children's Hospital, Stanford University School of Medicine; Chief Medical Officer, A.D.A.M., Inc., and Jacqueline A. Hart, M.D., Department of Internal Medicine, Newton-Wellesley Hospital, Boston, Ma. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited. | |||||||||
© Copyright HealthBasis 2006. All Rights Reserved. |